In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Subclinical atherosclerosis and its progression are modulated by perilipin-2 through a feed-forward loop between LXR and autophagy

Session Poster Session 1

Speaker Ewa Ehrenborg

Event : ESC Congress 2019

  • Topic : basic science
  • Sub-topic : Lipids, Metabolism
  • Session type : Poster Session

Authors : E Ehrenborg (Stockholm,SE), P Saliba Gustafsson (Stockholm,SE), M Pedrelli (Stockholm,SE), K Gertow (Stockholm,SE), S Pourteymour (Stockholm,SE), D Baldassarre (Milan,IT), E Tremoli (Milan,IT), U De Faire (Stockholm,SE), SE Humphries (London,GB), I Goncalves (Lund,SE), M Orho-Melander (Lund,SE), J Boren (Gothenburg,SE), P Eriksson (Stockholm,SE), J Magne (Stockholm,SE), P Parini (Stockholm,SE)

Authors:
E Ehrenborg1 , P Saliba Gustafsson1 , M Pedrelli1 , K Gertow1 , S Pourteymour1 , D Baldassarre2 , E Tremoli2 , U De Faire1 , SE Humphries3 , I Goncalves4 , M Orho-Melander4 , J Boren5 , P Eriksson1 , J Magne1 , P Parini1 , 1Karolinska Institute - Stockholm - Sweden , 2Cardiology Center Monzino IRCCS - Milan - Italy , 3University College London - London - United Kingdom of Great Britain & Northern Ireland , 4Lund University - Lund - Sweden , 5Sahlgrenska Academy - Gothenburg - Sweden ,

Citation:

Background: Hyperlipidemia is a major risk factor for cardiovascular disease and atherosclerosis is the underlying cause of both myocardial infarction and stroke. We have previously shown that the Pro251 variant of perilipin-2 reduces plasma triglycerides and may therefore be beneficial for atherosclerosis development.

Purpose: We sought to delineate putative beneficial effects of the Pro251 variant of perlipin-2 on subclinical atherosclerosis and the mechanism by which it acts.

Methods: A pan-European cohort of high-risk individuals where carotid intima-media thickness has been assessed was adopted. Human primary monocyte-derived macrophages were prepared from whole blood from individuals recruited by perilipin-2 genotype, or from buffy coats from the our University hospital blood central.

Results: The Pro251 variant of perilipin-2 is associated with decreased intima-media thickness at baseline and 30 months follow-up. Using human primary monocyte-derived macrophages from carriers of the beneficial Pro251 variant we show that this variant increases autophagy activity, cholesterol efflux, and a controlled inflammatory response. Through extensive mechanistic studies we demonstrate that increase in autophagy activity is accompanied with an increase in LXR activity and that LXR and autophagy reciprocally activate each other in a feed-forward loop, regulated by CYP27A1 and 27OH-cholesterol.

Conclusions: For the first time, we show that perilipin-2 affects susceptibility to human atherosclerosis through activation of autophagy and stimulation of cholesterol efflux. We demonstrate that perilipin-2 modulates levels of the LXR ligand 27OH-cholesterol and initiates a feed-forward loop where LXR and autophagy reciprocally activate each other; the mechanism by which perilipin-2 exerts its beneficial effects on subclinical atherosclerosis.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are